BenevolentAI vs Paige AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. BenevolentAI employs 100-500 people, while Paige AI has 100-500 employees.

BenevolentAI has raised more in total funding at $292M, compared to Paige AI's $125M — a gap of $167M.

Paige AI holds the higher Awaira Score at 65/100, compared to BenevolentAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 3-point gap that reflects meaningful differences in scale or traction.

BenevolentAI was founded by Joanna Shields in 2013. Paige AI was founded by Leo Grady in 2018. Visit each company's profile on Awaira for a full founder biography.

BenevolentAI: BenevolentAI applies machine learning to drug discovery, using knowledge graph technology and predictive AI models to identify novel drug candidates and repurpose existing compounds for new therapeutic applications. The London-based company has built a proprietary biomedical knowledge graph containing billions of data points extracted from scientific literature, clinical trial data, and genomic databases, which feeds its target identification and molecule generation pipelines.\n\nThe company went public on Euronext Amsterdam in 2022 via a SPAC merger with Odyssey Acquisition, having previously raised approximately $292 million in private funding from backers including SoftBank, Woodford Investment Management, and Mayfair Equity Partners. BenevolentAI has clinical-stage programs in atopic dermatitis and amyotrophic lateral sclerosis, developed from AI-generated hypotheses that were subsequently validated in wet lab experiments and progressed into human trials.\n\nBenevolentAI operates in the AI drug discovery sector alongside Recursion Pharmaceuticals, Exscientia, and Insilico Medicine. The company faces the inherent challenge of all computational drug discovery platforms in demonstrating that AI-generated candidates can survive clinical attrition at higher rates than traditionally discovered drugs. The platform is considered one of the more mature AI drug discovery systems in Europe, with the longest track record of moving AI-generated hypotheses into clinical development. Paige AI: Paige AI develops AI-powered pathology software that assists pathologists in identifying cancer and other diseases in digital whole-slide images. The platform received the first-ever FDA authorization for an AI-based primary diagnostic tool in pathology, a milestone that establishes regulatory precedent for clinical AI deployment in histopathology workflows.\n\nThe company raised approximately 125 million USD and partners with major academic medical centers and pathology laboratories to integrate its diagnostic AI into clinical workflows. Paige has expanded beyond prostate cancer detection into additional cancer types and is building a multi-cancer detection platform intended to function as a comprehensive AI layer across pathology departments.\n\nDigital pathology combined with AI represents one of the clearest near-term commercialization opportunities in medical AI, as the transition from glass slides to whole-slide imaging creates a digital substrate that AI can operate on at scale. Paige FDA clearance creates a significant regulatory moat that competitors must match before selling comparable diagnostic tools in the US market, giving the company a durable first-mover advantage in the AI-augmented pathology workflow.

BenevolentAI was founded first in 2013, giving it 5 years of additional market experience. Paige AI was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both BenevolentAI and Paige AI report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, BenevolentAI and Paige AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.